Fabrice ANDRE, MD
Gustave Roussy, Cancer Campus, Grand Paris · Gustave Roussy, Villejuif, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fabrice ANDRE, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07340619 · Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.UNICANCER · not yet recruiting · Metastatic (Stage IV) Melanoma · principal investigator
- Ph2NCT06680596 · Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd TherapyUNICANCER · recruiting · Breast Cancer Metastatic, Breast Cancer Stage IV · principal investigator
- Ph3NCT01805271 · Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone TherapyUNICANCER · active not recruiting · Primary Non-metastatic Breast Cancer, Who Remain Disease-free · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.